sábado, 16 de mayo de 2020

NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH/NIAID Template Banner

Thursday, May 14, 2020

NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19

SARS-CoV-2 virus particles
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19. The study will enroll approximately 2,000 adults in the United States with mild to moderate COVID-19.  Participants will be randomly assigned to receive short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Read More

No hay comentarios:

Publicar un comentario